局部抗生素预防呼吸机相关性肺炎研究中对照组死亡率的差异:一项伞状综述
该伞状综述纳入15篇系统评价引用的206项研究,比较局部抗生素研究中同期对照组、非同期对照组、干预组及无感染预防干预基准组的ICU死亡率。同期对照组平均ICU死亡率为28.5%(95%CI 25.0-32.3,n=41),高于基准组23.7%(19.2-28.5%,n=34)、非同期对照组23.5%(19.3-28.3%,n=14)及干预组24.4%(22.1-26.9%,n=62)。校正组平均年龄和发表年份后,同期对照组身份仍与较高死亡率相关(p=0.027),而其他组身份包括消毒剂研究组均为中性(p=无统计学意义)。作者认为同期对照组死亡率 inexplicably 偏高提示局部抗生素研究内存在溢出效应,其VAP和死亡率预防效果需谨慎解读。
要点
- 局部抗生素研究中同期对照组平均ICU死亡率28.5%(95%CI 25.0-32.3,n=41),高于无干预基准组23.7%(19.2-28.5%,n=34)。
- 同期对照组死亡率亦高于非同期对照组23.5%(19.3-28.3%,n=14)和局部抗生素干预组24.4%(22.1-26.9%,n=62)。
- 校正组平均年龄和发表年份后,同期对照组身份仍与较高死亡率相关(p=0.027),其他组身份均为中性(p=无统计学意义)。
- 干预组死亡率与文献衍生基准相似,而同期对照组死亡率 inexplicably 偏高,作者认为提示局部抗生素研究内存在溢出效应。
- 作者认为局部抗生素研究中显然的VAP和死亡率预防效果需谨慎解读。
适用人群与场景
- ICU患者,来自15篇系统评价引用的局部抗生素及其他感染预防干预研究。
研究设计与关键结果
- 伞状综述,纳入206项研究,复制了15篇系统评价中VAP和死亡率预防的汇总效应量。
- 局部抗生素研究同期对照组平均ICU死亡率28.5%(95%CI 25.0-32.3,n=41),高于基准组23.7%(19.2-28.5%,n=34)、非同期对照组23.5%(19.3-28.3%,n=14)及干预组24.4%(22.1-26.9%,n=62)。
- 校正组平均年龄和发表年份的荟萃回归模型中,局部抗生素研究同期对照组身份仍与较高死亡率相关(p=0.027),其他组身份包括消毒剂研究组均为中性(p=无统计学意义)。
证据类型、等级与局限
- 证据类型:伞状综述,纳入15篇系统评价引用的206项研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,局部抗生素研究中同期对照组死亡率 inexplicably 偏高提示研究内存在溢出效应,这些研究中显然的VAP和死亡率预防效果需谨慎解读。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To test the postulate that concurrent control patients within ICUs studying topical oropharyngeal antibiotics to prevent ventilator-associated pneumonia and mortality would experience spillover effects from the intervention.
DATA SOURCES: Studies cited in 15 systematic reviews of various topical antibiotic and other infection prevention interventions among ICU patients.
STUDY SELECTION: Studies of topical antibiotics, stratified into concurrent control versus nonconcurrent control designs. Studies of nondecontamination-based infection prevention interventions provide additional points of reference. Studies with no infection prevention intervention provide the mortality benchmark. Data from additional studies and data reported as intention to treat were used within sensitivity tests.
DATA EXTRACTION: Mortality incidence proportion data, mortality census, study characteristics, group mean age, ICU type, and study publication year.
DATA SYNTHESIS: Two-hundred six studies were included. The summary effect sizes for ventilator-associated pneumonia and mortality prevention derived in the 15 systematic reviews were replicated. The mean ICU mortality incidence for concurrent control groups of topical antibiotic studies (28.5%; 95% CI, 25.0-32.3; n = 41) is higher versus the benchmark (23.7%; 19.2-28.5%; n = 34), versus nonconcurrent control groups (23.5%; 19.3-28.3; n = 14), and versus intervention groups (24.4%; 22.1-26.9; n = 62) of topical antibiotic studies. In meta-regression models adjusted for group-level characteristics such as group mean age and publication year, concurrent control group membership within a topical antibiotic study remains associated with higher mortality (p = 0.027), whereas other group memberships, including membership within an antiseptic study, are each neutral (p = not significant).
CONCLUSIONS: Within topical antibiotic studies, the concurrent control group mortality incidence proportions are inexplicably high, whereas the intervention group mortality proportions are paradoxically similar to a literature-derived benchmark. The unexplained ventilator-associated pneumonia and mortality excess in the concurrent control groups implicates spillover effects within studies of topical antibiotics. The apparent ventilator-associated pneumonia and mortality prevention effects require cautious interpretation.
参考来源
- Hurley JC. Discrepancies in Control Group Mortality Rates Within Studies Assessing Topical Antibiotic Strategies to Prevent Ventilator-Associated Pneumonia: An Umbrella Review. Crit Care Explor. 2020. PMID: 32166296. doi:10.1097/CCE.0000000000000076
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。